145 related articles for article (PubMed ID: 12618228)
1. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
Arias C; González T; Moreno I; Caballero R; Delpón E; Tamargo J; Valenzuela C
Cardiovasc Res; 2003 Mar; 57(3):660-9. PubMed ID: 12618228
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.
Paul AA; Witchel HJ; Hancox JC
Br J Pharmacol; 2002 Jul; 136(5):717-29. PubMed ID: 12086981
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels.
Caballero R; Moreno I; González T; Arias C; Valenzuela C; Delpón E; Tamargo J
Circulation; 2003 Feb; 107(6):889-95. PubMed ID: 12591761
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
Teschemacher AG; Seward EP; Hancox JC; Witchel HJ
Br J Pharmacol; 1999 Sep; 128(2):479-85. PubMed ID: 10510461
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.
Walker BD; Singleton CB; Tie H; Bursill JA; Wyse KR; Valenzuela SM; Breit SN; Campbell TJ
Cardiovasc Res; 2000 Oct; 48(1):44-58. PubMed ID: 11033107
[TBL] [Abstract][Full Text] [Related]
7. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.
Mergenthaler J; Haverkamp W; Hüttenhofer A; Skryabin BV; Musshoff U; Borggrefe M; Speckmann EJ; Breithardt G; Madeja M
Naunyn Schmiedebergs Arch Pharmacol; 2001 Apr; 363(4):472-80. PubMed ID: 11330342
[TBL] [Abstract][Full Text] [Related]
8. Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Numaguchi H; Mullins FM; Johnson JP; Johns DC; Po SS; Yang IC; Tomaselli GF; Balser JR
Circ Res; 2000 Nov; 87(11):1012-8. PubMed ID: 11090546
[TBL] [Abstract][Full Text] [Related]
9. Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block.
González T; Arias C; Caballero R; Moreno I; Delpón E; Tamargo J; Valenzuela C
Br J Pharmacol; 2002 Dec; 137(8):1269-79. PubMed ID: 12466236
[TBL] [Abstract][Full Text] [Related]
10. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.
Moreno I; Caballero R; González T; Arias C; Valenzuela C; Iriepa I; Gálvez E; Tamargo J; Delpón E
J Pharmacol Exp Ther; 2003 Feb; 304(2):862-73. PubMed ID: 12538844
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HERG potassium channels by the antimalarial agent halofantrine.
Tie H; Walker BD; Singleton CB; Valenzuela SM; Bursill JA; Wyse KR; Breit SN; Campbell TJ
Br J Pharmacol; 2000 Aug; 130(8):1967-75. PubMed ID: 10952689
[TBL] [Abstract][Full Text] [Related]
12. Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels.
Franqueza L; Valenzuela C; Delpón E; Longobardo M; Caballero R; Tamargo J
Br J Pharmacol; 1998 Nov; 125(5):969-78. PubMed ID: 9846634
[TBL] [Abstract][Full Text] [Related]
13. Transient outward current inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes.
Cahill SA; Kirshenbaum LA; Gross GJ
J Cardiovasc Pharmacol; 2001 Sep; 38(3):460-7. PubMed ID: 11486250
[TBL] [Abstract][Full Text] [Related]
14. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
15. Bertosamil blocks HERG potassium channels in their open and inactivated states.
Zitron E; Karle CA; Wendt-Nordahl G; Kathöfer S; Zhang W; Thomas D; Weretka S; Kiehn J
Br J Pharmacol; 2002 Sep; 137(2):221-8. PubMed ID: 12208779
[TBL] [Abstract][Full Text] [Related]
16. {Omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels.
Guizy M; Arias C; David M; González T; Valenzuela C
Am J Physiol Cell Physiol; 2005 Nov; 289(5):C1251-60. PubMed ID: 15987770
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
Kushida S; Ogura T; Komuro I; Nakaya H
Eur J Pharmacol; 2002 Dec; 457(1):19-27. PubMed ID: 12460639
[TBL] [Abstract][Full Text] [Related]
18. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
Zhou Z; Gong Q; Ye B; Fan Z; Makielski JC; Robertson GA; January CT
Biophys J; 1998 Jan; 74(1):230-41. PubMed ID: 9449325
[TBL] [Abstract][Full Text] [Related]
19. Effects of Na+ channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells.
Wu LM; Orikabe M; Hirano Y; Kawano S; Hiraoka M
J Cardiovasc Pharmacol; 2003 Sep; 42(3):410-8. PubMed ID: 12960687
[TBL] [Abstract][Full Text] [Related]
20. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
